BioAtla Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancers. BioAtla Inc. applies its proprietary conditionally active biologic platform to create monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates designed to become active in the tumor microenvironment while limiting activity in healthy tissues. Its current portfolio includes product candidates aimed at difficult-to-treat cancers such as non-small cell lung cancer, sarcoma, melanoma, and head and neck squamous cell carcinoma. The company’s work centers on advancing targeted oncology programs that are intended to improve selectivity and therapeutic precision in cancer treatment. Headquartered in San Diego, California, BioAtla Inc. operates as part of the biotechnology sector and remains focused on research, development, and clinical evaluation of its antibody therapeutics.